Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

Management of Immunotherapy Toxicity in NSCLC

By Beth Eaby-Sandy, MSN, CRNP Posted: February 2018 When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was...

KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease

By Kara Nyberg, PhD Posted: August 2018 The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint...

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting...

PACIFIC Flooded Us with Optimism. Now What?

By Mirjana Rajer, MD, PhD Posted: April 1, 2019 For many years, the treatment of patients with stage III lung cancer has been a topic of intense...

Changing Landscape of Front-line Immunotherapy

By Naiyer A. Rizvi The rapid development of anti-PD-1 and PD-L1 antibodies in cancer underscores the tremendous impact they have had on the cancer landscape...

Exploring the Potential of Immuno-oncology Combination Therapy

By Cynthia L. Kryder, MS, CCC-Sp Posted: October 2017 Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy,...

Update on Checkpoint Inhibitors in Lung Cancer

By Erik J. MacLaren, PhD The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology,...

Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou

Posted: December 2018 In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical...

The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside

Posted: June 2017 By Cynthia L. Kryder, MS Decades of immunology research have shown that it is possible to harness the power of the immune system...

Expanding Opportunities for Patients to Be Treated with Immune Checkpoint Inhibition: Autoimmune Conditions, HIV,...

By Jarushka Naidoo, MB, BCH Posted: April 1, 2019 The U.S. Food and Drug Administration (FDA) has approved immune checkpoint inhibitors for multiple cancer types, including stage...

Meeting News